Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Co-Diagnostics ( (CODX) ) has shared an update.
On December 5, 2025, Co-Diagnostics, Inc. held a special meeting of shareholders where a proposal to amend the company’s Articles of Incorporation was approved. This amendment allows for a reverse stock split of the company’s common stock at a ratio between 1-for-2 and 1-for-30, with the final ratio to be determined by the board within twelve months. This decision could impact the company’s stock structure and potentially its market positioning.
The most recent analyst rating on (CODX) stock is a Hold with a $0.36 price target. To see the full list of analyst forecasts on Co-Diagnostics stock, see the CODX Stock Forecast page.
Spark’s Take on CODX Stock
According to Spark, TipRanks’ AI Analyst, CODX is a Neutral.
Co-Diagnostics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and profitability. While strategic initiatives and international expansion efforts are promising, the current financial challenges and bearish technical indicators weigh heavily on the score.
To see Spark’s full report on CODX stock, click here.
More about Co-Diagnostics
Co-Diagnostics, Inc. operates in the biotechnology industry, focusing on the development and commercialization of molecular diagnostics technologies. The company is known for its innovative products in the field of diagnostics, particularly for infectious diseases.
Average Trading Volume: 24,782,548
Technical Sentiment Signal: Sell
Current Market Cap: $23.53M
For detailed information about CODX stock, go to TipRanks’ Stock Analysis page.